bfw, if this drug lowers LDL and raises HDL (which seems to be at least 2 of the right things) and it failed what does it imply for apabetalone?

Does this bring us back to the multi-modal MOA of apabetalone with about 6 different impacts including impact on the complement cascade(positive impact on the Immune system), reduction in coagulation, reduction in mediators that promote calcium deposition in the vasculature, reductions in mediators that promote inflammation of the vasculature, increased ApoA-I – positive effects on lipid content of HDL, reduced oral glucose absorption & endogenous production?

Does it bring back to the impact on increasing Apoa-l or functional HDL?

Thanks

Toinv